Influence of Lenalidomide Treatment on Immune Effector Cells From High-Risk Smoldering Multiple Myeloma (SMM) Patients

• Published in: Blood Vol. 118; no. 21; p. 3944
• Main Authors: Paiva, Bruno, Mateos, Maria Victoria, López-Corral, Lucía, Vidriales, María-Belén, Hernandez, Miguel T., Bargay, Joan, de Arriba, Felipe, De La Rubia, Javier, Teruel, Ana-Isabel, Giraldo, Pilar, Rosiñol, Laura, Prosper, Felipe, Oriol, Albert, Hernández, Jose, Esteves, Graça, Leal da Costa, Fernando, Lahuerta, Juan José, Blade, Joan, San Miguel, Jesus F.
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 18.11.2011

Abstract 3944 Lenalidomide is an immunomodulatory agent that enhances T and NK cell activation, being this consideration as a major player in its anti-myeloma effect. However, in MM lenalidomide is usually combined with the immunosuppressant dexamethasone, which has raised questions regarding a pote...